M&A Deal Summary |
|
|---|---|
| Date | 2013-08-27 |
| Target | Hi-Tech Pharmacal Co. |
| Sector | Medical Products |
| Buyer(s) | Akorn |
| Deal Type | Add-on Acquisition |
| Deal Value | 640M USD |
| Advisor(s) | Nomura Investment Bank (Financial) Tashlik Goldwyn Levy ArentFox Schiff (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1971 |
| Sector | Life Science |
| Employees | 1,972 |
| Revenue | 1.1B USD (2016) |
Akorn, Inc. is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States and across the globe. Akorn, Inc. was founded in 1971 and is based in Lake Forest, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 5 |
| Sector: Medical Products M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 3 of 4 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 3 of 5 |
| Year: 2013 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-03-05 |
Advanced Vision Research
Woburn, Massachusetts, United States Advanced Vision Research, Inc. (“AVR”), a ophthalmic company that develops and markets eye care products under the TheraTears® and MacuTrition ® brand names. These products are used for dry eyes, eyelid hygiene, contact lens comfort and eye nutrition. |
Buy | $26M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-04-17 |
Akorn - 4 New Drug Applications
United States Akorn - 4 New Drug Applications includes Ciprofloxacin Hydrochloride Ophthalmic Solution, Levofloxacin Ophthalmic Solution and Lidocaine Hydrochloride Jelly and one product marketed under a New Drug Application: Lidocaine/Prilocaine Topical Cream. |
Sell | - |